A new era in the treatment of coronary disease?

European Heart Journal

Volumn 24, Issue 3, 2003, Pages 209-211

  Morice, Marie Claude ^a  

^a INSTITUT HOSPITALIER JACQUES CARTIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; DACTINOMYCIN; PACLITAXEL; RAPAMYCIN;

ANGIOGRAPHY; ARTERY INTIMA PROLIFERATION; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG ACTIVITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFECT; EDITORIAL; ELUTION; FOLLOW UP; HUMAN; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; CORONARY RESTENOSIS; COST-BENEFIT ANALYSIS; DRUG IMPLANTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS;

EID: 0037323224     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(02)00754-6     Document Type: Editorial

References (10)

1. Oesterle SN, Whitbourn R, Fitzgerald PJ et al. The stent decade: 1987-1997. Am Heart J 1998;136:578-99.
2. The STRESS Restenosis Study. NEJM 1994;331:496-501.
3. Braub-Dullaeus RC, Mann MJ, Dzaug VJ. Cell cycle progression - new therapeutic target for vascular proliferative disease. Circulation 1998;98:82-9.
4. Marx SO, Jayaraman T, Go LO et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76:412-7.
5. Poon M, Marx SO, Gallo R et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996;98:2277-83.
6. Chen D, Krasinski K, Sylvester A et al. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. J Clin Invest 1997;99:2334-41.
7. Sousa JE, Cost MA, Abizaid A et al. Lack of neointimal proliferation after implantation of Sirolimus-eluting stents in human coronary arteries. Circulation 2000;102:54-7.
8. Sousa JE. Late (Two-Year) follow-up from the First-in-Man (FIM) experience after implantation of Sirolimuseluting stents. 51st Scientific Sessions, American College of Cardiology [Oral Presentation].
9. Morice M-C, Serruys PW, Sousa J et al. Revascularization with a sirolimus-eluting versus an uncoated stent in patients with coronary artery disease. NEJM 2002;346:1773-80.
10. Van Belle E, Ketelers R, Bauters C et al. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: a key determinant of survival in diabetics after coronary balloon angioplasty. Circulation 2001;103:1218-24.